Sanofi Reaches For Post-Plavix Growth In Japan
While Sanofi’s Japanese pharma business is feeling the impact of generic competition to its former blockbuster top product, it is aiming to move back into growth through a string of planned launches over the next few years.
You may also be interested in...
Sanofi's Praluent looks set to become the second PCSK9 inhibitor available in Japan following a new recommendation for approval, but can it hold its own against launched rival Repatha? Meanwhile, AstraZeneca’s Brilinta is facing a delay.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.